{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:44:46Z","timestamp":1785282286617,"version":"3.55.0"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Rabbit immunogenicity studies on an experimental trivalent native outer membrane vesicle vaccine derived from three serogroup B strains were conducted to evaluate the effectiveness of this vaccine at inducing an antibody response with serum bactericidal activity against meningococcal strains of other serogroups in addition to serogroup B strains. The results showed that the vaccine was capable of inducing an effective broad-based bactericidal antibody response in rabbits against a small sample of<jats:named-content content-type=\"genus-species\">Neisseria meningitidis<\/jats:named-content>strains of serogroups C, W135, and X and, to a lesser extent, serogroups A and Y. Analysis of antibody specificity using a bactericidal depletion assay revealed that antibodies to lipooligosaccharide (LOS), PorA, and NadA induced in rabbits by the experimental trivalent outer membrane vesicle vaccine were responsible for most of the bactericidal activity against strains of the other<jats:named-content content-type=\"genus-species\">N. meningitidis<\/jats:named-content>serogroups. In the case of serogroup A<jats:named-content content-type=\"genus-species\">N. meningitidis<\/jats:named-content>strains, the outer membrane antigen NadA was primarily responsible for protection. The outer membrane antigens fHbp and OpcA were also effective in removing some bactericidal activity from the sera.<\/jats:p>","DOI":"10.1128\/cvi.00070-12","type":"journal-article","created":{"date-parts":[[2012,3,30]],"date-time":"2012-03-30T05:45:05Z","timestamp":1333086305000},"page":"659-665","source":"Crossref","is-referenced-by-count":17,"title":["Analysis of the Bactericidal Response to an Experimental Neisseria meningitidis Vesicle Vaccine"],"prefix":"10.1128","volume":"19","author":[{"given":"Elizabeth E.","family":"Moran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Burden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Joseph E.","family":"Labrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendell D.","family":"Zollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerian B.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2012,3,29]]},"reference":[{"key":"key20180919073604_B1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0092-1157(82)80010-3","article-title":"Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation","volume":"10","author":"Armand","year":"1982","journal-title":"J. Biol. Stand."},{"key":"key20180919073604_B2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1086\/597806","article-title":"Meningococcal factor H\u2013binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa","volume":"199","author":"Beernink","year":"2009","journal-title":"J. Infect. Dis."},{"key":"key20180919073604_B3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","article-title":"Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger","volume":"44","author":"Boisier","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"key20180919073604_B4","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1128\/CVI.00129-10","article-title":"Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults","volume":"17","author":"Bonvehi","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073604_B5","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1016\/j.vaccine.2009.07.036","article-title":"Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages","volume":"27","author":"Br\u00f6ker","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073604_B6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0264-410X(96)00020-5","article-title":"Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine","volume":"14","author":"Claassen","year":"1996","journal-title":"Vaccine"},{"key":"key20180919073604_B7","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis.","volume":"195","author":"Comanducci","year":"2002","journal-title":"J. Exp. Med."},{"key":"key20180919073604_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0019513","article-title":"Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso","volume":"6","author":"Delrieu","year":"2011","journal-title":"PloS One"},{"key":"key20180919073604_B9","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"key20180919073604_B10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"ii","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"key20180919073604_B11","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1128\/IAI.73.7.4070-4080.2005","article-title":"Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination","volume":"73","author":"Fisseha","year":"2005","journal-title":"Infect. Immun."},{"key":"key20180919073604_B12","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"key20180919073604_B13","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.129.6.1349","article-title":"Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J. Exp. Med."},{"key":"key20180919073604_B14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2010.12.039","article-title":"A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","volume":"29","author":"Keiser","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073604_B15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1128\/CVI.00542-10","article-title":"A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicles vaccines","volume":"18","author":"Koeberling","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073604_B16","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1073\/pnas.95.6.3140","article-title":"Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms","volume":"95","author":"Maiden","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"key20180919073604_B17","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1073\/pnas.0406805102","article-title":"Microsatellite instability regulates transcription factor binding and gene expression","volume":"102","author":"Martin","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"key20180919073604_B18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J. Exp. Med."},{"key":"key20180919073604_B19","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1128\/IAI.62.12.5290-5295.1994","article-title":"Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity","volume":"62","author":"Moran","year":"1994","journal-title":"Infect. Immun."},{"key":"key20180919073604_B20","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.vaccine.2010.11.072","article-title":"Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa","volume":"29","author":"Mothibeli","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073604_B21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3201\/eid1306.061395","article-title":"Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003","volume":"13","author":"Mueller","year":"2007","journal-title":"Emerg. Infect. Dis."},{"key":"key20180919073604_B22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.4269\/ajtmh.2009.80.619","article-title":"Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005\u20132006","volume":"80","author":"Mutonga","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"key20180919073604_B22a","article-title":"Guide for the care and use of laboratory animals","author":"National Research Council"},{"key":"key20180919073604_B23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1128\/JCM.44.3.861-871.2006","article-title":"Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989","volume":"44","author":"Norheim","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073604_B24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/CVI.00252-07","article-title":"Specificity of the sub-capsular antibody responses following serogroup A meningococcal disease in Ethiopian patients","volume":"15","author":"Norheim","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073604_B25","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.vaccine.2005.01.056","article-title":"Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B","volume":"23","author":"Pillai","year":"2005","journal-title":"Vaccine"},{"key":"key20180919073604_B26","doi-asserted-by":"crossref","first-page":"7752","DOI":"10.1016\/j.vaccine.2011.07.124","article-title":"An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups","volume":"29","author":"Pinto","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073604_B27","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":"Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra","volume":"16","author":"Reisinger","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073604_B28","first-page":"153","article-title":"From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine","author":"Van Den Dobbelsteen","year":"2004"},{"key":"key20180919073604_B29","first-page":"83","article-title":"Bacterial lipopolysaccharides","volume":"5","author":"Westphal","year":"1965","journal-title":"Extraction with phenol-water and further application of the procedure. Methods Carbohydr. Chem."},{"key":"key20180919073604_B30","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1128\/IAI.01108-08","article-title":"Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response","volume":"77","author":"Weynants","year":"2009","journal-title":"Infect. Immun."},{"key":"key20180919073604_B31","unstructured":"ZollingerWD ShoemakerD SaundersAG BrandtBL. May 2003. Vaccine against Gram negative bacteria. US patent 6,558,677 B2."},{"key":"key20180919073604_B32","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/CVI.00255-09","article-title":"Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity","volume":"16","author":"Zollinger","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073604_B33","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1016\/j.vaccine.2010.05.006","article-title":"Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine","volume":"28","author":"Zollinger","year":"2010","journal-title":"Vaccine"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00070-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:47:30Z","timestamp":1627591650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00070-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,29]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,4,26]]},"published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1128\/CVI.00070-12"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00070-12","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,29]]}}}